ARMO BioSciences Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Redwood City CA United States (2013)
Status: Acquired by Eli Lilly (2013)

Organization Overview

First Clinical Trial
2013
NCT02009449
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ARMO | ARMO BioSciences

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Colorectal Neoplasms (Phase 1)

Lung Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 12